Levamisole Withdrawal: EU Cites Brain Damage Risk

European regulators are recommending the withdrawal of levamisole-containing medications from the market due to the risk of a rare but serious neurological condition. The decision follows a comprehensive review by the European Medicines Agency (EMA), confirming concerns about the drug’s safety profile.

What is Levamisole and Why is it Being Withdrawn?

Levamisole is an anthelmintic medication used to treat parasitic worm infections, such as ascariasis and hookworm infections. It works by paralyzing susceptible worms, allowing the body to eliminate them. However, a recent EU-wide safety review determined that the benefits of levamisole no longer outweigh the risks for treating these infections, particularly given the availability of alternative treatments.

Leukoencephalopathy: A Serious Side Effect

The EMA’s safety committee, the Pharmacovigilance Risk Assessment Committee (PRAC), confirmed that leukoencephalopathy is a serious side effect of levamisole. Leukoencephalopathy damages the white matter of the brain, specifically the nerve fibers covered by myelin, which is crucial for efficient communication between brain regions. This condition can be debilitating and even life-threatening if left untreated, and diagnosis can be complex.

Symptoms and Onset

The PRAC review indicated that leukoencephalopathy can occur after a single dose of levamisole, and symptoms may develop up to several months after treatment. Symptoms to watch for include:

• Muscle weakness
• Difficulty speaking
• Confusion
• Difficulty controlling movements

Individuals who have been treated with levamisole and experience any of these symptoms should seek immediate medical attention. Medscape reports that the EMA urges prompt medical evaluation for anyone exhibiting these signs.

No Identified Risk Reduction Measures

The review did not identify any measures to reduce the risk of leukoencephalopathy associated with levamisole, nor were any specific groups found to be at higher or lower risk. This lack of mitigation strategies contributed to the decision to recommend withdrawal of the drug.

Alternative Treatments Available

The EMA emphasizes that other medications are authorized in the EU for the treatment of parasitic worm infections. Given the serious nature of levamisole-induced leukoencephalopathy and the availability of alternatives, the PRAC concluded that the risks associated with levamisole outweigh its benefits.

What This Means for Patients

The EMA recommends that marketing authorizations for levamisole-containing medicines be revoked across the EU. Healthcare providers are advised to inform patients about the risks and explore alternative treatment options. Patients currently taking levamisole should consult with their doctor to discuss alternative therapies.

Further information is available from the European Medicines Agency and national regulatory authorities.